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Abstract
In leukemia patients, stress and anxiety were suggested to predict poorer prognosis. Oncological patients experience ample
physiological and psychological stress, potentially leading to increased secretion of stress factors, including epinephrine,
corticosteroids, and prostaglandins. Here we tested whether environmental stress and these stress factors impact survival of
leukemia-challenged rats, and studied mediating mechanisms. F344 rats were administered with a miniscule dose of 60
CRNK-16 leukemia cells, and were subjected to intermittent forced swim stress or to administration of physiologically
relevant doses of epinephrine, prostaglandin-E2 or corticosterone. Stress and each stress factor, and/or their combinations,
doubled mortality rates when acutely applied simultaneously with, or two or six days after tumor challenge. Acute
administration of the b-adrenergic blocker nadolol diminished the effects of environmental stress, without affecting
baseline survival rates. Prolonged b-adrenergic blockade or COX inhibition (using etodolac) also increased baseline survival
rates, possibly by blocking tumor-related or normal levels of catecholamines and prostaglandins. Searching for mediating
mechanisms, we found that each of the stress factors transiently suppressed NK activity against CRNK-16 and YAC-1 lines on
a per NK basis. In contrast, the direct effects of stress factors on CRNK-16 proliferation, vitality, and VEGF secretion could not
explain or even contradicted the in vivo survival findings. Overall, it seems that environmental stress, epinephrine, and
prostaglandins promote leukemia progression in rats, potentially through suppressing cell mediated immunity. Thus,
patients with hematological malignancies, which often exhibit diminished NK activity, may benefit from extended b-
blockade and COX inhibition.
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Introduction
A considerable body of evidence implicates physiological stress
responses as modulators of the progression of several malignancies,
including tumors of the breast [1,2,3], skin [4,5], reproductive
system [6,7], and gastrointestinal tract [8,9]. Studies in tumor-
bearing patients suggest that cancer diagnosis and its treatment are
associated with substantial psychological and physiological distress
[10], which were reported to predict accelerated disease
progression [11,12]. Inversely, factors such as social support and
optimism were suggested to predict prolonged survival in cancer
patients [13], further hinting at a modulating impact of stress
responses and stress hormones in cancer progression.
While human studies are clearly limited in their ability to
delineate specific mechanisms mediating these alleged effects of
distress, animal studies have causally linked specific neuro-
endocrine stress responses to accelerated cancer progression
[3,4,5,14,15,16]. Activation of the sympathetic nervous system
(SNS) and the hypothalamic–pituitary–adrenal (HPA) axis was
implicated as facilitating cancer progression, as were pro-inflam-
matory factors and prostaglandins [3,14,17,18]. The mechanisms
through which these stress factors can affect tumor progression are
various. Studies have associated stress responses with suppression of
cell-mediated immunity (CMI). This suppression includes reduced
numbers of circulating CTL and NK cells, as well as reduced NK
activity [14,19] and reduced production of type-1 cytokines [20,21].
More recently, catecholamines and prostaglandins were shown to
directly influence specific tumor lines, promoting their progression
through several cellular mechanisms. These include improved
tumor cell invasion, migration, proliferation [22,23], and the tumor
releaseofpro-angiogenicfactorssuchasvascularendothelialgrowth
factor (VEGF) [24], as well as through decreased tumor anoikis (i.e.,
increased tumor cell survival after separation from the extracellular
matrix) [7]. Irrespective of whether stress hormones promote cancer
progression directly by affecting malignant cells, or indirectly by
suppressing host immunity or altering other aspects of host
physiology, it appears that stress hormones and pro-inflammatory
factors play a substantial role in the progression of solid tumors.
To date, these issues have not been directly addressed in the
context of leukemia; nonetheless, they may well be relevant.
Indeed, studies have shown that poorer prognosis in leukemia
patients is associated with suppressed CMI responses
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profile [29,30,31]. Accordingly, levels of autologous NK activity
were found to predict survival in leukemia patients [25,26], and
graft-versus-leukemia studies strongly suggest that an efficient NK
response after bone marrow transplantation can control acute
leukemia [32]. Over-expression of angiogenic/invasive factors,
including VEGF and MMP9, was found in patients with chronic
lymphocytic leukemia (CLL), and microvessel count in tumor
microenvironment was positively correlated to the clinical stage of
these patients [29,30,31].
Patients undergoing treatment for leukemia were reported to
exhibit high levels of anxiety and distress [33,34,35], and several
psychosocial aspects were implicated as prognostic factors in
leukemia, including quality-of-life, depression, and anxiety
[36,37]. However, it remains unclear whether patients’ stress
responses can be causally implicated in accelerating leukemia
progression or in increased mortality. Clinical and preclinical
studies addressing this question at the mechanistic or the
therapeutic level are scarce.
To address these issues in an animal model, in the current study
we used the CRNK-16 leukemia line which is syngeneic to the
F344 rat. This line originated from a naturally occurring leukemia
that is highly malignant and is the major cause of death in aged
F344 rats [38]. CRNK-16 cells were reported to form metastases
in the omentum, lymph nodes, spleen, liver, thymus and lungs
[38]. Our more recent work also established that administration of
a minuscule dose of 60 CRNK-16 cells is sufficient to induce
significant levels of mortality, and that this tumor expresses low
levels of MHC-I and is susceptible in vivo to lysis by NK cells, but
apparently not by adaptive immunity [39]. Thus, the CRNK-16
cell line provides an opportunity to study the effects of stress
hormones on leukemia progression in vivo in a biologically relevant
setting with potential clinical significance.
Hence, in the following studies, using this tumor line and
assessing survival rates in F344 rats, we tested (i) the effects of
administration of apparently biologically relevant doses of
epinephrine, corticosterone, and prostaglandin E2 (PGE2), (ii) the
impact of subjecting rats to stressful environmental conditions, and
(iii) the use of a b-blocker and a non-selective COX inhibitor in
stress and non-stress conditions. We also studied the in vivo impact
of these hormones (and that of CRNK-16 cells themselves) on NK
activity, as well as their in vitro direct effects on CRNK-16
proliferation, vitality, and VEGF secretion.
Materials and Methods
Animals
Male and female Fischer 344 rats (Harlan Laboratories,
Jerusalem) were housed 4 per cage, with saw-dust bedding, under
a 12:12 hours light/dark cycle at 2261uC, with free access to
standard food and fresh water. Animals were acclimatized to the
vivarium for at least 4 weeks, and were 12 to 16 weeks old at the
beginning of experimentation (in any given experiment, all
animals were of the same age), average weight was 260 g for
males and 175 g for females. All experiments were approved by
the Institutional Animal Care and Use Committee of Tel Aviv
University (permit number p-07-004), and all efforts were made to
minimize animal suffering.
General experimental procedure
Rats were handled on 3 consecutive days before each
experiment to reduce unwanted procedural stress. Gender and
the order of stress initiation, drug administration, and tumor
injection, were all counterbalanced across groups.
CRNK-16 tumor cells and their in vivo administration
The CRNK-16 cell line was kindly provided by Dr. W.H.
Chambers, from the University of Pittsburgh Cancer Institute.
Morphologically, these leukemia cells resemble large granular
lymphocytes (LGL), and are NKRP-1 (CD161) and CD45
positive, and CD3 negative [40]. Also, these cells constitutively
express the NK activation marker – gp42 [41], and the Ly49,
CD94 and NKG2-A/C receptors [42,43]. Cells were maintained
in complete medium (CM) (RPMI 1640 supplemented with 10%
heat-inactivated FCS, 50 mg/ml gentamicin, 2 mM L-glutamine,
0.1 mM non-essential amino acids and 1 mM sodium pyruvate
(purchased from Biological Industries, Beit Haemeq, Israel)) at
100% humidity, 5% CO2 at 37uC. CRNK-16 cells were
administered i.v. under light halothane anesthesia at a dose of
60 cells per rat suspended in 1 ml of PBS with 0.1% bovine serum
albumin.
Measurement of survival
In all experiments, rats were inspected for signs of morbidity
once or twice daily for a period of 80 days following tumor
injection. Animals were defined as morbid given two or more of
the following criteria: loss of more than 10% of body weight,
apathy, dehydration, red circles around the eyes, overt inactivity,
or paralysis. Based on our experience, these symptoms character-
ize a progressive phase of disseminated tumors, causing death
within approximately 24–48 hours. Animals defined as morbid
were euthanized and inspected to verify the development of
metastases. Tumor masses were established in various body
organs, including kidneys, bones, lymph nodes, lungs, liver and
colon. These animals were included in the mortality report, and
considered to have died on the next day. Animals that survived the
80-day period were euthanized and inspected for tumor masses or
irregularity in internal organs (specifically spleen, liver, kidney, and
all organs in the chest cavity) and for bone softness at this time
point. None of the survivors showed any signs of malignancy,
while all rats included in the mortality report exhibited one or
more signs of tumor development, and most had solid metastases.
In our previous study using this tumor model [39], we inspected
the surviving animals for an additional 3-month period and
recorded only 2 cases of mortality within more than 200 animals.
Thus, rats that survived this period are unlikely to later show
CRNK-16 related morbidity.
Environmental swim stress
A 5-gram weight was attached to the tails of stressed rats. Each
stressed rat was then placed for 3 minutes in a tank containing
water 35 centimeters deep, at 24uC, followed by a 3-minute rest
period. This procedure was repeated 5 times successively.
Environmental swim stress was counterbalanced across cages
(not within cage) in order to avoid unwanted stress in controls.
Materials
Prostaglandin E2 (PGE2; Sigma, Israel). In the survival
and NK activity studies (Exp. 1–5), PGE2 was first dissolved in
ethanol and then diluted in phosphate buffered saline (PBS),
reaching a final concentration of less than 10% ethanol in the
preparation. In order to maintain a relatively constant absorption
level, PGE2 was administered subcutaneously (0.8 mg/kg/ml) in a
slowly absorbed emulsion (consisting of 4 parts of the PBS/ethanol
preparation containing the active ingredient, 3 parts of mineral oil,
and 1 part of mannide-monooleate – a non specific surface active
emulsifier – all purchased from Sigma, Israel). Based on our
experience, using various compounds, this emulsion prolongs the
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essential when compounds with a short half-life, such as PGE2 and
epinephrine, are used. Control rats were administered with the
exact same emulsion excluding the PGE2. As PGE2 acts locally in
a paracrine/autocrine manner [44], the relevancy of its systemic
serum level is unclear. Nevertheless, this dose, administered in the
slowly absorbed emulsion, is apparently physiologically relevant, as
its effects on several immune indices, are equivalent to those of
surgical stress, and can be blocked by doses of COX inhibitors
similar to those needed to block physiological effects after surgery
[3,17,19]. For the in vitro experiments (Exp. 6–7), PGE2 was
dissolved and diluted to a concentration of 1.43610
23 M in 20%
ethanol and 80% PBS, and further diluted in CM to the final
concentrations (10
26 Mt o1 0
28 M).
Epinephrine (Sigma, Israel). In the survival and NK
activity studies, epinephrine was administered subcutaneously
(0.5 mg/kg) in the aforementioned slowly absorbed emulsion.
Epinephrine was first dissolved in the PBS fraction of the
emulsion. This dose, administered in the slowly absorbed
emulsion, is apparently physiologically relevant, as its effects on
several immune indices are equivalent to those of environmental
swim stress and surgical stress, and can be blocked with the same
doses of b-blockers used to block the effects of these environmental
stressors (unpublished data from our laboratory). Control rats were
administered with the exact same emulsion excluding the
epinephrine. For the in vitro experiments, epinephrine was
dissolved and diluted in CM to the final concentrations (10
25 M
to 10
27 M).
Corticosterone (Sigma, Israel). In the survival and NK
activity studies, corticosterone was dissolved overnight in corn oil
and administered subcutaneously at a dose of 3 mg/kg, twice,
5 hours apart. This dose induces physiological high levels of
plasma corticosterone (500–800 ng/ml) for 4–5 hours per
injection [45], which are similar to levels reached after exposure
to environmental stressors [14]. Control rats were administered
twice with corn oil at the same time points. For the in vitro
experiments, corticosterone was dissolved in ethanol to a
concentration of 0.03 M and further diluted in CM to the final
concentrations (10
26 Mt o1 0
28 M).
Nadolol (Sigma, Israel), a hydrophilic nonselective b-adrener-
gic antagonist, which does not cross the blood-brain-barrier. In
Exp. 3, nadolol was dissolved in PBS and injected twice
subcutaneously: 10 minutes prior to environmental swim stress,
at a dose of 0.4 mg/kg, and again 60 minutes after environmental
swim stress, i.e., with tumor injection, at a dose of 0.2 mg/kg. In
Exp. 4, the second injection was administered in the aforemen-
tioned slowly absorbed emulsion at a dose of 4.5 mg/kg nadolol.
Control rats were administered twice with the appropriate vehicles
at the same time points. For the in vitro experiments, nadolol was
dissolved and diluted in CM to the final concentrations (10
25 Mt o
10
27 M).
Indomethacin (Sigma, Israel), a nonselective COX inhibitor,
with a slight preference to COX-1 inhibition, and a half-life of
about 4 hours in rats [46]. Indomethacin was dissolved in
propylene glycol and administered subcutaneously (4 mg/kg,
2 ml/kg). Control rats were administered with the propylene
glycol.
Metaproterenol (Sigma, Israel), a moderately selective b2-
adrenergic receptor agonist, was dissolved and diluted in CM to
the final concentrations (10
25 Mt o1 0
27 M).
Flow Cytometry of NK and CRNK-16 cells
FACS analysis was used to assess the concentration of
granulocytes, lymphocytes, T, NKT, and NK cells in the blood
(Exp. 5) and to count CRNK-16 cells and determine their vitality
(Exp. 7). Lymphocytes and granulocytes were identified accord-
ing to their forward and side scatters. As described previously by
Chambers et al. [47], NK cells were identified as being above a
level of fluorescence intensity that distinguishes between bright
and dim populations of CD161 positive cells. This previous study
also demonstrated that CD161 is expressed by 94% of blood
LGL cells of the rat, and that the NK cytolytic activity was totally
contained in the CD161
bright cell population. Thus, NK cells
were herein identified as CD161
bright lymphocytes, based on
FITC-conjugated anti-CD161 labeling and scatter properties
[48]. T cells were identified as CD5
+CD161
2 and NKT cells as
CD5
+CD161
+, based on PE-conjugated anti-CD5 labeling and
scatter properties. CRNK-16 cells were studied in a separate
experiment, and were the only cell type in the FACS preparation.
To assess the total numbers of each specific subset per microliter
of blood, (Exp. 5) and the number of CRNK-16 cells per well
(Exp. 7), we added 20 mm polystyrene microbeads (Duke
Scientific, Palo Alto, CA) at a concentration of 600/ml of sample
studied. Following cytometry, the formula: CD161
bright6micro-
beads/600 was used to calculate NK cell concentrations and
similar formulas were used for each other subset of leukocytes
(and for CRNK-16 cells). The coefficient of variation for this
method was found in our laboratory to be 6% for identical
samples. In order to determine CRNK-16 vitality, cells were
stained with 7-amino-actinomycin D (7-AAD), a ready-to-use
solution for the exclusion of nonviable cells in flow cytometric
analysis (for details see Schmid et al. [49]).
Assessment of blood NK Activity (cytotoxicity)
Preparation of blood effector cells. Rats were anesthetized
with isoflurane, and 1 ml of blood was withdrawn by cardiac
puncture into syringes containing 30 units of heparin. Whole
blood was then washed once with PBS and twice with CM. This
method was used to remove sera while maintaining the original
composition of leukocytes in the blood.
Preparation of target cells. CRNK-16 and YAC-1 [50]
cells were washed with CM. Both CRNK-16 cells and YAC-1 cells
(5610
6 of each) were incubated for 1 h with 100 mCi
51Cr (Danyel
Biotech, Rehovot, Israel) in 100 ml saline, 100 ml heat-inactivated
fetal calf serum (FCS), and 75 ml CM. Following incubation, cells
were washed three times in CM (3006g for 10 minutes) and
adjusted to a concentration of 5610
4/ml.
NK activity (cytotoxicity) assay. The standard whole-blood
4 hour
51Cr release assay was used to assess leukocyte anti-tumor
cytotoxicity against the CRNK-16 syngeneic line and the standard
YAC-1 line. This procedure was previously described elsewhere
[19]. To create four different effector-to-target (E:T) ratios, blood
effector cells were serially diluted (1:2) beginning at 1/4 of their
original concentration in the blood, and co-incubated with a fixed
number of target cells. Specifically, aliquots of 150 ml of effector
cell suspension (from washed blood) were placed in wells of a
microtiter plate and serially diluted to create the 4 E:T ratios. 5000
labeled target cells (CRNK-16 or YAC-1) in 100 ml complete
media were then added to each well. Plates were centrifuged
(400 g610 min) and incubated at 37uC, 100% humidity, for
4 hours. Plates were then centrifuged again and 100 mlo f
supernatant was removed from each well and counted in a
gamma counter to determine experimental
51Cr release.
Spontaneous release was obtained from wells containing target
cells and CM only, and total release was obtained from wells
containing 1% Triton X-100. Percent cytotoxicity was calculated
by the following formula: Percent Cytotoxicity=1006
[(experimental release minus spontaneous release)/(total release
Stress Responses and Leukemia Progression
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that cytotoxicity in this assay depends on NK cells, since their
selective depletion nullified all specific cytotoxicity.
Assessment of Cytotoxicity per NK Cell. Since we
recorded the number of NK cells in each sample tested for
cytotoxicity, we were able to mathematically align samples’ NK
cell concentration, according to the FACS analysis, to achieve
common NK:CRNK-16 or NK:YAC-1 ratios, thereby assessing
NK cytotoxicity on a per NK cell basis.
In vitro ELISA assessment of supernatant VEGF levels
Standard R&D (Minneapolis, MN, USA) ELISA kits were used
according to manufacturer’s instructions.
In vitro EIA assessment of serum PGE2 levels
Standard Cayman Chemicals (Ann Arbor, MI, USA) EIA kits
were used according to manufacturer’s instructions.
Radio-Immuno-Assay for serum Corticosterone levels
A standard
125I double-antibody RIA kit (MP Biomedicals,
Solon, OH, USA) was used according to the manufacturer’s
instructions.
Statistical analysis
For statistical analysis of the survival experiments (Exp. 1–4), the
Kaplan-Meier model of survival was used, followed by the
Tarone-Ware test for pair-wise group comparisons. For experi-
ments 5, 6 and 7, one- or two-way analyses of variance (ANOVA)
were used to analyze percent cytotoxicity (NK activity), VEGF
levels, and cell numbers and vitality. Provided significant group
differences were indicated by ANOVA for experiment 5, Fisher’s
Protected Least Significant Differences (PLSD) contrasts were used
to test specific pair-wise differences with respect to our
hypothesized effects: PGE2, epinephrine and corticosterone will
reduce NK activity compared to controls. Provided significant
group differences were indicated by ANOVA for experiments 6–7,
Scheffe’ post hoc contrasts were used. For all experiments, p values
of less than 0.05 were considered significant, and p values of 0.05–
0.1 were considered marginally significant.
Results
Experiment 1: Epinephrine and PGE2, but not
corticosterone, significantly reduced survival rates
Epinephrine (0.5 mg/kg s.c. in a slowly absorbed emulsion),
PGE2 (0.8 mg/kg s.c. in a slowly absorbed emulsion) and
corticosterone, (2 injections of 3 mg/kg s.c., 5 hours apart) or
their respective vehicles (slowly absorbed emulsion or corn oil)
were each administered simultaneously with tumor injection.
Experiment 1a: effects of PGE2 administration on
survival. Female rats were injected with either PGE2 (n=20)
or vehicle (n=25). As indicated in Fig. 1A, PGE2 administration
significantly decreased survival rates (Kaplan-Meier model,
Tarone-Ware, p,0.05).
Experiment 1b: effects of epinephrine and corticosterone
administration on survival. Male rats were injected with
either epinephrine (n=18), corticosterone (n=24), a combination
of the two (n=16), or vehicle (n=26). As indicated in Fig. 1B,
epinephrine alone, or co-administered with corticosterone,
significantly decreased survival rates as compared to vehicle-
treated rats (Kaplan-Meier model, Tarone-Ware, p,0.05 and
p,0.05, respectively). Corticosterone alone did not significantly
alter survival rates.
Experiment 2: Co-administration of epinephrine and
corticosterone decreases survival rates when given
simultaneously with tumor transfer or 2 or 6 days later
Male and female rats were co-administered with epinephrine
(0.5 mg/kg s.c. in a slowly absorbed emulsion) and corticosterone
(3 mg/kg s.c.; twice, 5 hours apart), simultaneously with (n=30), 2
days (n=26) or 6 days (n=26) after tumor injection, or
administered with the relevant vehicles at these time points (total
of 34 rats). As indicated in Fig. 2, co-administration of epinephrine
and corticosterone significantly decreased survival rates when
injected simultaneously with tumor cells (Kaplan-Meier model,
Tarone-Ware, p,0.05), but less so when injected 2 or 6 days
thereafter (Kaplan-Meier model, Tarone-Ware, p=0.066,
p,0.11, respectively), as compared to vehicle-treated rats. When
the two groups of 2 and 6 days were combined into one ‘‘delayed
Figure 1. Effects of PGE2, epinephrine and corticosterone administration on survival rates. (A) PGE2 (&, n=20), administered
simultaneously with tumor injection, significantly decreased survival rates compared to vehicle (%, n=25) administration (control). (B) Epinephrine,
alone (#, n=18) or in combination with corticosterone (half-filled circles, n=16), significantly decreased survival rates, compared to vehicle control
treatment (%, n=26), while corticosterone (N, n=24) did not cause a significant effect.
doi:10.1371/journal.pone.0019246.g001
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the vehicle control group, was evident (Kaplan-Meier model,
Tarone-Ware, p,0.05).
Experiment 3: Environmental swim stress reduces
survival rates, and the b-adrenergic antagonist, nadolol,
blocks this effect
To ascertain that physiological levels of stress hormones released
endogenously under stressful conditions can affect survival rates,
the following study was conducted. Male rats were either subjected
to environmental swim stress, or served as controls and remained
undisturbed in their home cages. In each group, rats were either
treated with the non-specific b-blocker, nadolol, or injected with
saline (n=29–30/group). Nadolol was subcutaneously injected at
0.4 mg/kg, 10 minutes prior to the beginning of the environmen-
tal swim stress procedure, followed by 0.2 mg/kg, 1 hour after the
termination of the procedure, at the time of tumor injection. PGE2
serum levels were also measured in stressed and non stressed rats.
As indicated in Fig. 3, in saline-treated rats, environmental swim
stress significantly decreased survival rates (Kaplan-Meier model,
Tarone-Ware, p,0.05) compared to non-stressed controls.
Nadolol, which had no effect on survival of non-stressed rats,
significantly blocked the deleterious effect of environmental swim
stress on survival (p,0.05). PGE2 serum levels were unaffected by
environmental swim stress compared to controls.
Experiment 4: Improving survival rates by targeting
tumor-associated or baseline levels of catecholamines
and prostaglandins
Given that epinephrine and PGE2 decreased survival rates, we
herein tested whether endogenous levels of these hormones, which
are not induced by environmental stressful conditions, can also
impact survival rates. The mere in vivo presence of leukemia may
increase plasma levels of stress hormones and PGE2. Many tumors
were shown to secrete PGE2 [53,54,55], presumably to suppress
anti-tumor immunity, and the general stress response of the host
toward a disease includes various stress-related factors [56].
Therefore, we tested whether antagonizing tumor-associated or
baseline levels of prostaglandins or catecholamines for 24–
48 hours following tumor challenge can improve survival rates.
Specifically, one hour before tumor injection, male rats were
administered with either: (i) nadolol (an acute loading dose of
0.4 mg/kg s.c. dissolved in saline, followed by an additional
4.5 mg/kg maintenance dose in a slowly absorbed emulsion given
with tumor injection; n=25), (ii) indomethacin (4 mg/kg i.p.;
n=25), (iii) a combination of (i) and (ii) (n=26), or (iv) their
vehicles (n=45). As indicated in Fig. 4, indomethacin significantly
increased survival rates, both alone (Kaplan-Meier model,
Tarone-Ware, p,0.05) and in combination with nadolol (Tar-
one-Ware, p,0.05), whereas nadolol alone only marginally
Figure 2. Time dependent effects of co-administration of
epinephrine and corticosterone on survival rates. Co-adminis-
tration of epinephrine and corticosterone simultaneously with tumor
injection (&, n=30) significantly decreased survival rates. Administra-
tion of the same drug combination, 2 (+, n=26) or 6 (m, n=26) days
after tumor injection, led to a smaller decrease in survival rates,
becoming significantly lower than control (%, n=34) when these
groups were combined.
doi:10.1371/journal.pone.0019246.g002
Figure 3. Effects of environmental swim stress and nadolol
treatment on survival of leukemic rats. Survival rates of non-
stressed rats, treated with an acute administration of nadolol (%, n=29)
or vehicle (#, n=30) were compared to those of stressed rats, treated
with nadolol (&, n=29) or vehicle (N, n=30). Environmental swim
stress significantly decreased survival rates. This effect was blocked by
nadolol, which did not significantly affect the survival of non-stressed
rats.
doi:10.1371/journal.pone.0019246.g003
Figure 4. Effects of targeting tumor-associated and/or baseline
levels of prostaglandins and catecholamines in CRNK-16-
bearing rats. Indomethacin, with (half-filled circles, n=26) or without
(N, n=25) a prolonged administration of nadolol, significantly
improved survival rates. Nadolol alone (#, n=25) marginally improved
survival (p=0.058), compared to vehicle (%, n=45) control treatment.
doi:10.1371/journal.pone.0019246.g004
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p,0.058), compared to vehicle-treated rats.
Experiment 5: In vivo administration of PGE2,
epinephrine, or corticosterone reduces NK activity
without significantly affecting NK cell numbers
Male rats were injected with epinephrine, corticosterone, PGE2,
60 CRNK-16 cells or vehicle (n=8–10 per group). Ninety minutes
or 48 hours later, blood was withdrawn by cardiac puncture from
all rats and assayed for NK activity against the syngeneic CRNK-
16 and the standard YAC-1 line (see methods). Serum levels of
PGE2 and corticosterone were also measured. As indicated in
Fig. 5, 90 minutes after their administration, corticosterone,
epinephrine and PGE2, each significantly reduced NK activity
on a per NK level (p,0.05), against both tumor lines, while
CRNK-16 cell administration significantly increased NK activity
against the YAC-1 line. Forty-eight hours after administration, no
differences in NK activity were found between groups against both
lines.
NK cell numbers were not significantly affected by the
treatments, although other cell types (e.g., T and NKT cells) were
significantly changed at 90 minutes (See Table S1), but not at
48 hours (See Table S2).
Ninety minutes after drug/tumor injection, corticosterone
serum levels were significantly increased in the epinephrine and
PGE2 groups, and significantly decreased in the CRNK-16 group
(See Fig. S1). Administration of PGE2 significantly elevated PGE2
serum levels to maximum detection levels (,2000 pg/ml) at
90 minutes, which returned to baseline levels at 48 hours. These
levels were unaffected by other treatments, compared to vehicle
(See Fig. S2).
Experiment 6: CRNK-16 does not secrete VEGF,
spontaneously or in the context of stress hormones or
PGE2
Experiment6a:CRNK-16cellsexhibitundetectablelevelsof
VEGF secretion. CRNK-16 cells were washed in CM and
incubated in 24-well flat-bottomed plates (500,000 cells in 1 ml
CM per well). YAC-1 T-cell lymphoma [50], B16 melanoma [57],
3LL Lewis lung carcinoma [58], and the MADB106 mammary
adenocarcinoma [59] cell lines were also incubated under the same
conditions and served as positive controls. The control condition
included CM without tumor cells. The plates were incubated at
100% humidity, 37uC, 5% CO2. Supernatant fluid was harvested
after incubation of 1, 3 and 5 days, and assayed for murine VEGF
using ELISA kits (R&D, Minneapolis, MN, USA). All cell lines
spontaneously secreted VEGF, while the CRNK-16 line showed
undetectable VEGF secretion levels at all times (see Fig. 6).
Experiment 6b: No impact of PGE2, corticosterone, and
catecholamine associated drugs on VEGF secretion by
CRNK-16. Some tumor lines were reported to increase their
VEGF secretion when incubated for 3 or 6 hours with
catecholamines [60]. Although CRNK-16 cells did not
spontaneously secrete detectable levels of VEGF, we tested
Figure 5. Effects of administration of epinephrine, corticosterone, PGE2 and CRNK-16 cells on NK activity. Ninety minutes (but not
48 hours) after their administration, epinephrine, corticosterone and PGE2, each significantly decreased NK activity against both the standard YAC-1
and the syngeneic CRNK-16 lines. Administration of CRNK-16 cells (n=10/time point) increased NK activity against YAC-1 line, compared to vehicle
control treatment at 90 minutes, but not 48 hours. Data are presented as mean+SEM (n=10/group/time point).
doi:10.1371/journal.pone.0019246.g005
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cells were washed in CM and incubated in 24-well flat-bottomed
plates with our standard CM with or without fetal calf serum, for 3
or 6 hrs (500,000 cells in 1 ml CM per well). Additionally, wells
were supplemented with either: (i) norepinephrine (10
25 M/
10
26 M/10
27 M); (ii) metaproterenol (10
25 M/10
26 M/10
27 M);
(iii) corticosterone (10
26 M/10
27 M/10
28 M); (iv) prostaglandin
E2 (10
26 M/10
27 M/10
28 M); (v) nadolol (10
25 M/10
26 M/
10
27 M); (vi) ethanol (10
26 M/10
27 M/10
28 M) which served as
vehicle control for PGE2 and corticosterone (vii) CM control
without any drugs. None of the hormones and drugs listed above
induced VEGF production in the CRNK-16 cell line (data not
shown).
Experiment 7: Corticosterone and PGE2, but not
epinephrine or metaproterenol, decreased CRNK-16
proliferation and vitality in vitro
CRNK-16 cells were washed in CM and incubated in a 96-well flat-
bottomed plate (30,000 cells in 200 mlC Mp e rw e l l )w i t he i t h e r :( i )
epinephrine (10
25 M/10
26 M/10
27 M); (ii) metaproterenol (10
25 M/
10
26 M/10
27 M); (iii) corticosterone (10
26 M/10
27 M/10
28 M); (iv)
PGE2 (10
26 M/10
27 M/10
28 M); (v) ethanol (10
26 M/10
27 M/
10
28 M) which served as vehicle control for PGE2 and corticosterone
(vi) CM control without any drugs. After 24 or 48 hours of incubation,
cells were collected from each well, counted and inspected for
vitality using flow cytometry (see methods). Plates were then
inspected under the microscope and no adhering cells were
found. Under control conditions, CRNK-16 cells proliferated and
increased their numbers approximately 3-fold per day. No
differences were found between different control groups (v and
vi) and therefore these groups were combined. The impacts of
hormones and drugs were very similar at 24 (See Fig. S3 in
Supporting Information) and 48 hours (Fig. 7); PGE2 and
corticosterone decreased cell proliferation by approximately
50% (Fig. 7: A; p=0.0241 and p=0.0053 at 48 hrs, respectively)
and cell vitality by approximately 10% (Fig. 7: B; p,0.0001 at
48 hrs), in a dose-dependent manner.
Discussion
The present study clearly demonstrates that stressful conditions
and physiologically relevant doses of stress hormones and
prostaglandins can significantly increase mortality rates of
leukemic rats. To the best of our knowledge, this is the first
thorough investigation conducted in the realm of hematological
tumors, specifically leukemia, causally demonstrating marked
adverse effects of stress hormones and PGE2 on survival rates of
leukemic animals. Specifically, our data showed that, in rats
already bearing leukemia (for two or six days), exposure to a
combination of epinephrine and corticosterone, for only several
hours, significantly decreased survival rates. When these stress
hormones were administered simultaneously with leukemia cells,
an approximate 3-fold decrease in survival rates was evident.
PGE2 and epinephrine by themselves caused similar effects, while
corticosterone alone had smaller and non-significant effects. To
test the impact of environmentally induced physiological stress
responses, we employed a short paradigm of swim stress and found
that the endogenous neuroendocrine responses markedly reduced
survival rates of the CRNK-16 challenged rats. Furthermore, an
acute administration of the b-blocker, nadolol, significantly
attenuated this effect of stress, without affecting survival rates of
non-stressed animals. Even in the absence of external stressful
stimuli, tumor-associated or baseline levels of PGE2 and
epinephrine contributed to the progression of CRNK-16 leuke-
mia, as the prolonged administration of the b-blocker (nadolol) or
of a COX inhibitor (indomethacin) significantly improved survival
Figure 6. Spontaneous secretion of VEGF by different malig-
nant cell lines. YAC-1 T-cell lymphoma, B16 melanoma, 3LL Lewis lung
carcinoma, and the MADB106 mammary adenocarcinoma cells served
as positive controls and secreted increasing amounts of VEGF on days 1,
3 and 5, while CRNK-16 showed undetectable levels.
doi:10.1371/journal.pone.0019246.g006
Figure 7. In vitro effects of stress hormones and PGE2 on CRNK-16 proliferation and vitality at 48 hours. Corticosterone and PGE2
reduced CRNK-16 cell proliferation and vitality in a dose dependent manner at 48 h. Epinephrine and metaproterenol did not affect proliferation (A)
and vitality (B) rates. Data are presented as mean+SEM. * indicates a significant difference from the control group. Drug concentrations ranged from
10
28 Mt o1 0
25 M, see Exp. 7 for details.
doi:10.1371/journal.pone.0019246.g007
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wide window of opportunity to affect CRNK-16 progression (i.e.
administered at 0, 2, and 6 days following tumor transfer), it seems
expected that chronic exposure to the blockers (Exp. 4), but not
acute exposure (Exp. 3), will increase survival rates that are
modulated by the continuous tumor-associated or baseline levels of
prostaglandins and catecholamines. In accordance with these
findings, and using the same CRNK-16 model, we also recently
reported that in leukemic rats undergoing surgery, which are
clearly subjected to long-lasting high endogenous levels of
catecholamines and prostaglandins, the combination of indometh-
acin and nadolol in a slow-release preparation significantly
improved survival rates [2]. It is worthy to note, though, that in
the current study we did not compare concentrations of nadolol in
the blood between the acute and chronic administration
procedures, and thus both the duration and the concentrations
of the drug may underlie the difference between acute and chronic
exposure. Overall, these and our previous findings demonstrate
the deleterious impacts of endogenous stress hormones and PGE2
on survival of leukemia-bearing animals.
Immune suppression has long been suggested as a key mediator
of the effects of stress responses on tumor progression. The
sympathetic nervous system innervates all lymphoid organs [61],
and lymphocytes (including NK cells and cytotoxic T cells) express
receptors for catecholamines [62,63], prostaglandins [64,65], and
glucocorticoids [66]. Stimulation of these receptors affects cytokine
release [66], controls proliferation [67] and cell distribution
[68,69,70,71], and has repeatedly been shown to suppress many
aspects of CMI, NK cell and CTL activity in particular
[17,48,72,73]. However, in order to relate reduced survival rates,
as evident in the current study, to suppression of CMI, one needs
to establish a role for CMI in controlling CRNK-16 progression.
Indeed, we previously reported that the CRNK-16 line exhibits
reduced expression levels of MHC-I [39], as is common in many
human cancers including leukemia [74]. This common escape
mechanism, efficient vis-a `-vis adaptive immunity, facilitates
detection and destruction of tumor cells by innate immunity,
specifically NK cells [75,76]. Moreover, we reported that the
CRNK-16 tumor line is sensitive to NK-lysis in vitro, and that
selective in vivo depletion of NK cells markedly decreased survival
rates of CRNK-16 challenged rats [39]. Therefore, it can be
concluded that stress-induced changes in NK activity are expected
to modulate CRNK-16 progression. Hence, in the current study,
we tested whether the observed effects of stress hormones and
PGE2 on survival are associated with reduced NK activity. Indeed,
our results indicated a significant decrease in NK activity against
both the syngeneic CRNK-16 and the standard YAC-1 tumor
lines following administration of epinephrine, corticosterone, or
PGE2, and this reduction was mostly ascribed to reduced activity
per NK cell. This suppression was evident at 90 minutes post
hormone administration, but not two days later, as expected given
the transient nature of the effects of these hormones on NK
activity. We have previously shown that the swim stress paradigm
used herein also suppresses NK activity [77] for a limited period of
time [78]. These findings further strengthen (but do not prove) the
proposed mediating role of CMI suppression in the effects of stress
on leukemia progression.
These findings are in agreement with clinical findings indicating
that the status (number and activity) of NK cells in leukemia
patients is a predictor of prognosis [25,26]. A potential role for NK
cells in the rejection of leukemia is further suggested by the clinical
efficacy of allogeneic bone marrow transplantation using non-
identical HLA donors. Studies have shown [32] that implantations
using selective mismatch in appropriate HLA loci (specifically NK
KIR ligand) were more effective than matched combinations,
enabling a graft-versus-leukemia activity due to the failure of
recipient’s leukemic cells to inhibit donor’s NK cells through KIR
receptors.
As expected, and given known in vivo interactions between
epinephrine [79], PGE2 [80] and corticosterone, the administra-
tion of PGE2 and epinephrine in the current study transiently
increased corticosterone serum levels. Surprisingly, the adminis-
tration of a miniscule dose of 60 CRNK-16 cell transiently
reduced corticosterone serum levels (at 90 minutes, but not at
48 hours) and increased NK activity levels against YAC-1 target
cells. A potential mediator that may explain both findings could be
a transient CRNK-16-induced secretion of IL-12, as IL-12 was
reported to reduce corticosterone serum levels [81] and increase
NK cytotoxicity [2].
As was discussed in the introduction, mechanisms other than
immune modulation could mediate the effects of stress on tumor
progression. In fact, several recent studies indicated that
catecholamines can directly influence tumor cells, activating
cellular pathways essential for their survival and growth. For
example, the production of pro-angiogenic factors [24,60],
including VEGF, and of tumor invasion related enzymes, such
as MMP2 and MMP9 [82], was upregulated in vitro by
norepinephrine in several human and non-human cancers,
through the b-adrenergic-cAMP-PKA pathway in tumor cells. In
the current study and in our previous study [39], CRNK-16
bearing rats eventually developed disseminated tumors in various
organs [38], which could then benefit from the release of such pro-
angiogenic and invasion-promoting factors. In fact a role for
VEGF was recently found in the in vivo progression of two animal
leukemia lines [83]. Therefore, we tested whether CRNK-16
tumor cells produce VEGF and/or if this production is induced or
augmented by compounds which we found here to reduce survival
rates. We observed no spontaneous secretion of VEGF by CRNK-
16, nor secretion following exposure to norepinephrine, the b-
agonist metaproterenol, PGE2, or corticosterone. In contrast,
other rodent tumor cells which we tested herein, all of which are
solid tumors, did secrete VEGF spontaneously.
It was also reported that activation of b-adrenergic receptors
[84] or of glucocorticoid receptors [85,86] can sometimes directly
induce tumor proliferation and increase tumor vitality, although
there is also evidence to the contrary [87,88,89]. Thus, we studied
the in vitro proliferation and vitality of the CRNK-16 line when
incubated with the aforementioned compounds at a range of
doses. In contrast to the prediction that these hormones would
facilitate tumor progression, as may have been suggested by the
outcomes of our in vivo survival studies, we found that
corticosterone and PGE2 actually reduced in-vitro tumor cell
proliferation and vitality (by approximately 50% and 10%,
respectively), while epinephrine and metaproterenol had no
effects. Overall, these findings reduce the likelihood of direct
effects of stress hormones/PGE2 on CRNK-16 cells as a potential
mediating mechanism of the in vivo effects of these hormones on
survival rates, and strengthen the proposed role for CMI
suppression. However, these findings do not negate other direct
effects of stress hormones on CRNK-16 cells that might promote
their survival, invasion capacity, or other angiogenic related
processes in the more complex in vivo milieu.
Patients undergoing treatment for hematological malignancies
experience high levels of anxiety and depression [33,34,35]. These
two psychological factors were repeatedly linked to profound CMI
suppression through the release of stress hormones [11,90,91], and
were also associated with poor survival in leukemia patients [92].
In addition, NK activity has been reported to be compromised in
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the need for clinical studies testing the use of b-blockers, COX
inhibitors, and approaches to limit cortisol levels, as potential
interventions in leukemia patients aimed at restoring NK function
and improving survival rates under stressful and apparently non-
stressful conditions. COX inhibitors and b-blockers are used in
numerous clinical settings with relatively minimal side effects,
although contraindications may clearly occur under some
conditions. Semi-selective COX-2 inhibitors may be advanta-
geous, as they are believed to cause fewer adverse reactions than
non-selective COX inhibitors [94], and non-selective b-blockers
could prove superior to selective b1-blockers, as immunocytes
express both b1 and b2 receptors [95]. Overall, this study
underlines the importance of considering stress responses, initiated
by internal or external stimuli, in the clinical setting of leukemia
treatment, specifically addressing the potential beneficial effects of
b-blockers and COX inhibitors.
Supporting Information
Figure S1 Effects of administration of epinephrine,
corticosterone, PGE2 and CRNK-16 cells on corticoste-
rone serum levels. Ninety minutes (but not 48 hours) after their
administration, epinephrine and PGE2, each significantly in-
creased corticosterone serum levels. Administration of CRNK-16
cells significantly decreased corticosterone levels at 90 minutes,
compared to vehicle controls. Data are presented as mean+SEM
(n=10/group/time point).
(TIF)
Figure S2 Effects of administration of epinephrine,
corticosterone, PGE2 and CRNK-16 cells on PGE2 serum
levels. Ninety minutes after its administration, PGE2 significantly
increased PGE2 serum levels compared to vehicle controls to
values beyond maximum detection levels, these values were
calculated by extrapulation of standard curve. 48 hours after
administration, levels were returned to baseline. Data are
presented as mean+SEM (n=10/group/time point).
(TIF)
Figure S3 In vitro effects of stress hormones and PGE2
on CRNK-16 proliferation and vitality at 24 hours.
Corticosterone and PGE2 reduced CRNK-16 cell proliferation
and vitality in a dose dependent manner at 24 h. Epinephrine and
metaproterenol did not affect proliferation (A) and vitality (B)
rates. Data are presented as mean+SEM. * indicates a significant
difference from the control group. Drug concentrations ranged
from 10
28 Mt o1 0
25 M, see Exp. 7 for details.
(TIF)
Table S1 Effects of administration of epinephrine,
corticosterone, PGE2 and CRNK-16 cells on numbers
of leukocyte subsets at 90 minutes. Ninety minutes after
their administration, epinephrine and PGE2 significantly reduced
numbers of circulating lymphocytes, and specifically, T cells.
PGE2 and injection of CRNK-16 cells also reduced numbers of
circulating NKTs. * indicates a significant difference from the
control group. Data are presented as mean (SEM).
(DOC)
Table S2 Effects of administration of epinephrine,
corticosterone, PGE2 and CRNK-16 cells on numbers
of leukocyte subsets at 48 hours. Fourty-eight hours after
drug/tumor administration, no significant differences were found
between the groups in numbers of circulating leukocyte subsets.
Data are presented as mean (SEM).
(DOC)
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